Drug Profile
Cisplatin liposomal inhaled - Eleison Pharmaceuticals
Alternative Names: ILC; Inhaled cisplatin - Insmed; Inhaled lipid cisplatin; Inhaled lipid-complexed cisplatin (ILC); Lipid cisplatin complexLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator Insmed
- Developer Eleison Pharmaceuticals
- Class Antineoplastics; Platinum complexes; Small molecules
- Mechanism of Action DNA cross linking agents; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Cancer metastases; Osteosarcoma
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 May 2021 Eleison Pharmaceuticals receives patent allowance for cisplatin liposomal inhaled in Canada
- 28 May 2021 Eleison Pharmaceuticals plans a phase III trial for Small cell lung cancer (Inhalation) in 2021 or 2022
- 28 Apr 2021 No recent reports of development identified for clinical-Phase-Unknown development in Non-small-cell-lung-cancer in Unknown (Inhalation)